Health Systems Governance and Financing, World Health Organization (WHO), Geneva, Switzerland.
Science Division, World Health Organization (WHO), Geneva, Switzerland.
Int J Health Policy Manag. 2021 Nov 1;10(11):697-705. doi: 10.34172/ijhpm.2020.245.
World Health Organization Choosing Interventions that are Cost-Effective (WHO CHOICE) has been a programme of the WHO for 20 years. In this latest update, we present for the first time a cross-programme analysis of the comparative cost-effectiveness of 479 intervention scenarios across 20 disease programmes and risk factors.
This analysis follows the standard WHO CHOICE approach to generalized cost-effectiveness analysis applied to two regions, Eastern sub-Saharan Africa and Southeast Asia. The scope of the analysis is all interventions included in programme specific WHO CHOICE analyses, using WHO treatment guidelines for major disease areas as the foundation. Costs are measured in 2010 international dollars, and benefits modelled beginning in 2010, or the nearest year for which validated data was available, both for a period of 100 years.
Across both regions included in the analysis, interventions span multiple orders of magnitude in terms of cost-effectiveness ratios. A health benefit package optimized through a value for money lens incorporates interventions responding to all of the main drivers of disease burden. Interventions delivered through first level clinical and non-clinical services represent the majority of the high impact cost-effective interventions.
Cost-effectiveness is one important criterion when selecting health interventions for benefit packages to progress towards universal health coverage (UHC), but it is not the only criterion and all calculations should be adapted to the local context. To support country decision-makers, WHO CHOICE has developed a downloadable tool to support the development of data for this criterion.
世界卫生组织选择具有成本效益的干预措施(WHO CHOICE)已经开展了 20 年。在最新的更新中,我们首次对 20 个疾病规划和风险因素下的 479 个干预方案的相对成本效益进行了跨方案分析。
该分析遵循 WHO CHOICE 标准方法进行广义成本效益分析,适用于撒哈拉以南非洲东部和东南亚两个地区。分析范围包括特定疾病规划的 WHO CHOICE 分析中包含的所有干预措施,并以主要疾病领域的世卫组织治疗指南为基础。成本以 2010 年国际元衡量,效益从 2010 年开始建模,或根据可用的经过验证的数据,在 100 年内建模。
在所分析的两个地区中,干预措施在成本效益比方面跨越了多个数量级。通过货币价值视角优化的健康效益一揽子计划包含了针对疾病负担主要驱动因素的干预措施。通过第一级临床和非临床服务提供的干预措施代表了大多数具有高影响力和成本效益的干预措施。
成本效益是为实现全民健康覆盖(UHC)而选择健康干预措施纳入效益一揽子计划的一个重要标准,但不是唯一标准,所有计算都应适应当地情况。为支持国家决策者,WHO CHOICE 开发了一个可下载的工具,以支持该标准的数据开发。